Text or call a human:Text (808) 600-9260Call
CorporateVentureCapital.com

JJDC

Profile, fund size and portfolio

Parent Johnson & JohnsonHQ New Brunswick, United StatesFounded 1973

JJDC is the corporate venture arm of Johnson & Johnson, a healthcare company. It was founded in 1973 and is based in New Brunswick, United States. It invests from Series A to Series C+. Sectors it names: biotech and life sciences, medical devices, healthcare and digital health.

Cumulative investedS11
USD 3.4bn+

Every figure links to its source

Snapshot

Investment stage: Series A to Series C+
Data behind this graphic
Data behind this graphic
ItemValue
Stage rangeSeries A to Series C+
SectorsBiotech and life sciences, Medical devices, Healthcare and digital health
GeographyNorth America, Europe, Asia (Portfolio companies by region, from the firm's portfolio page)
OfficesNew Brunswick, United States, London, United Kingdom, San Francisco, United States, San Diego, United States, Cambridge, United States

Sources: S9 Johnson & Johnson Innovation news feed (public JSON used by the site); S3 JJDC one-pager for JPM 2026 (PDF): biotech investment team and 2025 private investments.

Graphic 1 of 3

Investment stage: Series A to Series C+

Sources: S9 Johnson & Johnson Innovation news feed (public JSON used by the site); S3 JJDC one-pager for JPM 2026 (PDF): biotech investment team and 2025 private investments.

Download:Report a correction
Investments closed by country
Data behind this graphic
Data behind this graphic
ItemCompaniesShare
North America1963.3%
Europe826.7%
Asia310%

Portfolio companies by region, from the firm's portfolio page

Sources: S9 Johnson & Johnson Innovation news feed (public JSON used by the site); S3 JJDC one-pager for JPM 2026 (PDF): biotech investment team and 2025 private investments.

Graphic 2 of 3

Investments closed by country

Sources: S9 Johnson & Johnson Innovation news feed (public JSON used by the site); S3 JJDC one-pager for JPM 2026 (PDF): biotech investment team and 2025 private investments.

Download:Report a correction
Scale and capital allocated
Data behind this graphic
Data behind this graphic
MeasureValueUnitKindSource
Headline sizeUSD 3.4bn+Cumulative investedStated by the firm or its parentS11
Companies backed100+companiesReported in the pressS13
Companies on the firm's portfolio page27companiesCounted from the firm's own listS3

Sources: S11 Global Venturing Powerlist 2025: Chris Picariello; S13 LinkedIn post by J&J Innovation (Jan 2025): 50 new and follow-on investments in 2024; S3 JJDC one-pager for JPM 2026 (PDF): biotech investment team and 2025 private investments.

Graphic 3 of 3

Scale and capital allocated

Firms and databases count companies, rounds and investments differently.

Sources: S11 Global Venturing Powerlist 2025: Chris Picariello; S13 LinkedIn post by J&J Innovation (Jan 2025): 50 new and follow-on investments in 2024; S3 JJDC one-pager for JPM 2026 (PDF): biotech investment team and 2025 private investments.

Download:Report a correction

Where it invests and who leads it

Geography

Headquarters
New Brunswick, United States
Offices

Portfolio companies by regionS9S3

  • North America19 · 63%
  • Europe8 · 27%
  • Asia3 · 10%

Portfolio companies by region, from the firm's portfolio page

LeadersS4S6S5S7S8

JJDC on LinkedIn

Key facts

FactValueStatusSource
Parent companyJohnson & Johnson (NYSE: JNJ)Single sourceS10
Parent industryHealthcare and life sciencesSingle sourceS10
Founded1973Single sourceS10
HeadquartersNew Brunswick, United StatesSingle sourceS3
StatusActiveSingle sourceS1
Capital sourceParent company onlySingle sourceS10
Headline sizeUSD 3.4bn+ (Cumulative invested)Single sourceS11
Companies backed100+Single sourceS13
People on the team page10Single sourceS3
StagesSeries A, Series C+ (inferred from announced rounds)EstimateS9

Recent rounds

DateCompanyRoundAmountLed by the firmSource
2024-08-19HistoSonicsSeries C+USD 102MNoS9
2024-06-14Bright Peak TherapeuticsSeries C+USD 90MNoS9
2024-03-21Asgard TherapeuticsSeries AEUR 30MNoS9
2024-01-30Accent TherapeuticsSeries C+USD 75MNoS9
2023-07-14Solenic MedicalSeries AUSD 5.1MYesS9

Notable outcomes

IPOs and acquisitions of portfolio companies. Price shown only where published.

CompanyTypeYearAcquirer or exchangeSource
TibotecAcquisition2002Johnson & JohnsonS10
V-WaveAcquisition2024Johnson & Johnson MedTechS11
Cue HealthIPO2021NasdaqS15
Legend BiotechIPO2020NasdaqS15

Portfolio

The firm's portfolio page lists 27 companies.S3

The firm also states 100+ companies backed. The page list and the stated total measure different things.S13

Shared portfolio with other corporate VCs

15 companies on the JJDC portfolio page also appear on the portfolio page of at least one other firm in this directory. Matched by company website, or by name where no website is published.

FirmSharedCompanies in common
GV5EpiBiologics, Accent Therapeutics, Ankyra Therapeutics, Mestag Therapeutics, Perceive Bio
Novartis Venture Fund3EpiBiologics, Citryll, ONL Therapeutics
Pfizer Ventures2Nucleome Therapeutics, TRexBio
Roche Venture Fund1EpiBiologics
Taiho Ventures1EpiBiologics
AbbVie Ventures1Accent Therapeutics
Chugai Venture Fund1Stylus Medicine
Neva SGR1Stylus Medicine
Ionis Pharmaceuticals Strategic Investments1Aro Biotherapeutics
Koch Disruptive Technologies1Artera
Boehringer Ingelheim Venture Fund1Asgard Therapeutics
M Ventures1Astraveus

Companies backed by the most corporate VCs

Every company on the JJDC list

27 companies, as listed on the firm's own website.S3 Read the firm's list.

  • Abdera Therapeutics
  • Accent Therapeutics
  • Ankyra Therapeutics
  • Arialys Therapeutics
  • Aro Biotherapeutics
  • Artera
  • Asgard Therapeutics
  • Astraveus
  • AviadoBio
  • Bright Peak Therapeutics
  • Cellular Origins
  • CirCode Biomed
  • Citryll
  • DAC Biotech
  • EpiBiologics
  • Flindr Therapeutics
  • LinkCell Therapeutics
  • Mestag Therapeutics
  • Nucleome Therapeutics
  • ONL Therapeutics
  • PAQ Therapeutics
  • Perceive Bio
  • Prazer Therapeutics
  • Rondo Therapeutics
  • SonoThera
  • Stylus Medicine
  • TRexBio

History

  1. JJDC formed as the venturing arm of Johnson & Johnson.S10
  2. Chris Picariello becomes president of JJDC.S12
  3. 50th anniversary.S10
  4. 50 new and follow-on investments.S13
  5. JPM 2026 one-pager lists 2025 private investments and three portfolio M&As.S3

About Johnson & Johnson

ItemDetailSource
Listed asNYSE: JNJS15
HeadquartersUnited StatesS10

Official pages

Read the firm's own pages for current information.

  • Website jnjinnovation.com/venture-investing-jjdc

Sources

  1. S1Johnson & Johnson Innovation: Venture investing at JJDCFirm
  2. S3JJDC one-pager for JPM 2026 (PDF): biotech investment team and 2025 private investmentsFirm
  3. S4Johnson & Johnson Innovation: Chris PicarielloFirm
  4. S5Johnson & Johnson Innovation: Tamir MeiriFirm
  5. S6Johnson & Johnson Innovation: Fiona MacLaughlinFirm
  6. S7Johnson & Johnson Innovation: Sanjay MistryFirm
  7. S8Johnson & Johnson Innovation: Nancy OndovikFirm
  8. S9Johnson & Johnson Innovation news feed (public JSON used by the site)Firm
  9. S10Global Venturing: How Johnson & Johnson Innovation lasted 50 decades (27 Oct 2022)Press
  10. S11Global Venturing Powerlist 2025: Chris PicarielloPress
  11. S12Global Venturing: J&J picks Picariello to replace Heyman (20 Nov 2019)Press
  12. S13LinkedIn post by J&J Innovation (Jan 2025): 50 new and follow-on investments in 2024Press
  13. S14FundingWatcher corporate venture capital listThird-party report
  14. S15SEC EDGAR full-text search: 'Johnson & Johnson Innovation - JJDC'Filing

Disclaimer and corrections

Not affiliated. This page is not affiliated with, endorsed by or sponsored by JJDC or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.

Spotted a mistake? Report a correction.